BioCentury
VerifiedOnline/Digital
Since 1993, BioCentury, Inc. has been internationally recognized as the leading provider of value-added information, analysis and data for biotechnology and pharmaceutical companies, investors, academia and government on the strategic issues essential to the formation, development and sustainability of life science ventures.
BioCentury employs a fully integrated multimedia platform — including publications, video, online data solutions and conferences — to provide its audience with authoritative and up-to-date intelligence about corporate strategy, partnering, emerging technology, clinical data, public policy and the financial markets.
BioCentury's Editorial and Research staff comprise industry-recognized business and science editors and writers. The Company's management team includes executives with backgrounds in international business, publishing, finance, and the biotech and pharmaceutical industries.
BioCentury is headquartered in Redwood City, Calif., with offices in Washington, D.C.; Chicago; and London. Source
Actions
Media Outlet details
| Scope | International, Trade/B2B |
|---|---|
| Language | English |
| Country | United States of America |
Similarweb UVM
|
Request pricing |
Comscore UVM
|
Request pricing |
Recent Articles
Search ArticlesFDA taking another look at eye therapy rejected under Makary
ARTICLE | Regulation Advisory committee to consider low-dose atropine from Sydnexis following FDA setback By Steve Usdin, Washington Editor For eight months, Sydnexis has argued that FDA's rejection of SYD-101, its low-dose atropine drop for pediatric myopia, contradicted widely accepted medical practice. The company has garnered support from ophthalmologists, the editorial page of The Wall Street Journal, and politicians. Now it will make that case to an advisory committee.
With first clinical data due next year, Scribe to test IPO market: Finance Report
ARTICLE | Finance Plus: Kelun’s follow-on in Hong Kong; venture rounds for Alchemab, Pyrotech, Cyllene, BriStar and Fore By Paul Bonanos, Director of Biopharma Intelligence, and Lindsay Martin, Biopharma Analyst With its first gene silencing therapy now in clinical testing, in vivo CRISPR company Scribe has become the latest biotech to file for an IPO. The start-up, co-founded by gene editing pioneer Jennifer Doudna, entered the NASDAQ queue just before the July 4 holiday weekend began.
FDA resumes CRL releases, citing ‘commitment to transparency’
ARTICLE | Regulation New batch of complete response letters includes camrelizumab plus rivoceranib combo from Hengrui and Elevar By Steve Usdin, Washington Editor Just days after HHS confirmed that FDA had paused the release of complete response letters for unapproved drugs, the agency has released 16 CRLs. Friday’s release underscores the Trump administration’s “steadfast commitment to transparency,” an HHS spokesperson told BioCentury.... Just want immediate access to this one article?
Perspective — siRNAs are better than ASOs
ARTICLE | Editor's Commentary Why it might be time to just admit that siRNAs are the better modality By Stephen Hansen, Director of Biopharma Intelligence I think we may have reached the point at which we can just say that siRNAs are better therapeutic molecules than antisense oligonucleotides.
2Q26 Wrap: Income inequality
PRESENTATION | Finance Winners, losers in biotech stock tiers in 2Q26 By Meredith Durkin Wolfe, Director of Research Biopharma stocks in 2Q26 were a story of the rich getting richer, with the top two tiers both seeing gains while the lower three all fell. Gains in the upper tiers were enough to push them positive for the first half overall, recuperating from 1Q26 when all groups saw losses. The $10 billion or more starting valuation class gained a median of 3%, with 29 companies up and 15 down.
Can M&A momentum carry biotech through year-end?
ARTICLE | Finance M&A enthusiasm is carrying biotech amid tepid reception for launches. What happens if the AI trade goes bust? By Stephen Hansen, Director of Biopharma Intelligence A historic run of M&A drovebiotech’s outperformance in the first half of the year, with most investors expecting dealmaking to continue to support the sector through 3Q26. Heading into the summer months, biotech’s public markets are in a good place. Financings are being upsized and showing good postmarket performance.
New CEO appointments include Idorsia, Arrakis leaders
ARTICLE | Management Tracks Plus: New hires at Jeito, Stipple, Vera and more By BioCentury Staff Jean-Paul Clozel’s temporary return to the CEO role at Idorsia Ltd. (SIX:IDIA) is due to end on Oct. 1, when Roland Wandeler assumes the role. Clozel has been interim CEO since March, when Srishti Gupta stepped down from the role; NovaBridge Biosciences said last week that Gupta has become its next CEO. Wandeler will join from Grifols S.A. (Madrid:GRF; NASDAQ:GRFS), where he is president of biopharma...
Science Spotlight: Actionable pathways for cachexia and radioresistance in lung cancer
ARTICLE | Discovery & Translation BioCentury’s translational roundup also includes a muscle-specific PROTAC platform and a dual tumor and TME-targeting CAR T therapy for glioblastoma By Danielle Golovin, Senior Biopharma Analyst Two recent papers identify new levers for drug developers in lung cancer: one for systemic symptoms, and one for treatment resistance.
Roivant’s Gline: From spin-cos to commercial conviction
CEO Matt Gline on upcoming launch, portfolio construction, and AI in biotech R&D By Lindsay Martin, Biopharma Analyst Roivant CEO Matt Gline calls the company’s move beyond spinning out subsidiary “vants” to concentrating on late-stage development and commercial priorities less a pivot than an evolution toward an original goal, which could soon be realized with the approval and launch of brepocitinib this year. Gline became CEO of Roivant Sciences Ltd.
Ionis’ ATTR-CM miss: Were overlapping mechanisms or the modality to blame?
ARTICLE | Product Development Eplontersen from Ionis, AZ misses in Phase III ATTR-CM study By Lauren Martz, Executive Director, Biopharma Intelligence and Tierney Baum, Biopharma Analyst A Phase III miss for one of the most highly anticipated clinical trials of the year doesn’t just set Ionis and partner AstraZeneca back billions of dollars in peak revenue; it also highlights a vulnerability of one of the modalities that was expected to transform the management of cardiovascular disease.